Abstract
BackgroundImmune checkpoint blockade (ICB) induces durable response in approximately 20% of patients with advanced bladder urothelial cancer (aUC). Over 50% of aUCs harbor genomic alterations along the phosphoinositide 3-kinase (PI3K)...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have